Perspective Therapeutics, Inc. (CATX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q3 '24: 369K Q4 '24: 234K Q1 '25: 342K Q2 '25: 290K Q3 '25: 209K Q4 '25: 43K Q1 '26: 76K Q2 '26: 81K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

-500K 0 500K 1M 1.5M Q1 '22: 1.4M Q2 '22: 926K Q3 '22: 414K Q4 '22: -414K Q1 '23: 487K Q2 '23: 248K Q3 '23: 738K Q4 '23: -39K Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '24: -18.6M Q4 '24: -45M Q1 '25: -21.8M Q2 '25: -24M Q3 '25: -27.9M Q4 '25: -39.8M Q1 '26: -28.3M Q2 '26: -29.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -15.1M Q4 '24: -40.2M Q1 '25: -18.2M Q2 '25: -21.5M Q3 '25: -26M Q4 '25: -37.5M Q1 '26: -26.2M Q2 '26: -26.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 700K 1.4M 2.1M Q4 '21: 1.6M Q1 '22: 1.5M Q2 '22: 1.6M Q3 '22: 1.3M Q4 '22: 1.4M Q1 '23: 1.6M Q2 '23: 1.8M Q3 '23: 1.4M Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: 3.4M Q4 '24: -26.6M Q1 '25: -21.6M Q2 '25: -20M Q3 '25: -16.3M Q4 '25: -24.7M Q1 '26: -31.5M Q2 '26: -20.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -26.3M Q4 '24: -41.2M Q1 '25: -26.2M Q2 '25: -21M Q3 '25: -18.3M Q4 '25: -29.7M Q1 '26: -38.3M Q2 '26: -34.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '24: 49.5M Q2 '24: 66.6M Q3 '24: 70.6M Q1 '25: 72.4M Q2 '25: 74.2M Q3 '25: 74.3M Q1 '26: 103.6M Q2 '26: 120.7M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.80 -1.20 -0.60 0.00 0.60 1.20 1.80 Q3 '24: -1.55 Q4 '24: -1.25 Q1 '25: -1.25 Q2 '25: -1.36 Q3 '25: -1.50 Q4 '25: -1.40 Q1 '26: -1.40 Q2 '26: -1.33 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.